The comparison of countries’ PGx policies in the context of CBZ therapy showed substantial similarities, and observed differences can be attributed to the varying prevalence of HLA-A or HLA-B associated with CBZ-induced SJS/TENS and the degree of progress of PGx practice in each country. This evidence concerns the gene HLA-B and Schwartz-Jampel syndrome.